Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aligos Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Aligos Therapeutics, Inc.

ALGS

Aligos Therapeutics, Inc.

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapeutics for liver diseases and viral infections, including chronic hepatitis B virus (HBV), metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. Its pipeline features small molecule and oligonucleotide drug candidates designed to improve treatment outcomes by targeting viral lifecycles and metabolic pathways. Aligos leverages proprietary platforms, in-licensing, and internal expertise to create potentially best-in-class therapies for large unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aligos Therapeutics, Inc.

1
1
Aligos Therapeutics, Inc. Aligos Therapeutics Reports Revenue Surge to $2.8M but Faces $23M Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Aligos Therapeutics, Inc. Aligos Therapeutics Reports Annual Financial Results and Operational Updates for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Aligos Therapeutics, Inc. Aligos Therapeutics Reports $31.5 Million Net Loss in Q3 2025, Increased Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aligos Therapeutics, Inc. Aligos Therapeutics Reports $15.9 Million Net Loss in Q2 2025, Despite Improved Financial Position

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aligos Therapeutics, Inc. Aligos Therapeutics Reports $43.1 Million Net Income in Q1 2025, Driven by Fair Value Gain

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aligos Therapeutics, Inc. Aligos Therapeutics Reports $131.2 Million Net Loss for 2024, Revenue Declines

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Aligos Therapeutics, Inc. Aligos Therapeutics Reports Significant Financial Decline, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments